{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:37:47Z","timestamp":1761917867134},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,20]]},"DOI":"10.4103\/0366-6999.245277","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T13:03:30Z","timestamp":1542027810000},"page":"2658-2665","source":"Crossref","is-referenced-by-count":6,"title":["Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy"],"prefix":"10.1097","volume":"131","author":[{"given":"Dan-Dan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Song","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Chun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1463-1326.2011.01414.x","article-title":"Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans","volume":"13","author":"Ahr\u00e9n","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1507\/endocrj.K10E-382","article-title":"Sitagliptin reduces albuminuria in patients with type 2 diabetes","volume":"58","author":"Hattori","year":"2011","journal-title":"Endocr J"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40256-013-0043-2","article-title":"Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: A pilot study","volume":"13","author":"Tani","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/VHRM.S39300","article-title":"Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment","volume":"9","author":"Lukashevich","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of \u03b2-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","article-title":"Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"14","author":"Haak","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr Rev"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.2337\/dc14-0865","article-title":"The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications","volume":"37","author":"Avogaro","year":"2014","journal-title":"Diabetes Care"},{"key":"R16-3-20210129","first-page":"663","article-title":"Biochemical and immunological properties of urinary angiotensinase A and dipeptidylaminopeptidase IV. Their use as markers in patients with renal cell injury","volume":"30","author":"Scherberich","year":"1992","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1479164111434318","article-title":"Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease","volume":"9","author":"Sun","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/ki.2015.103","article-title":"Interactions of DPP-4 and integrin \u03b21 influences endothelial-to-mesenchymal transition","volume":"88","author":"Shi","year":"2015","journal-title":"Kidney Int"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.04.055","article-title":"Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy","volume":"761","author":"Jung","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3389\/fphar.2017.00780","article-title":"Saxagliptin attenuates albuminuria by inhibiting podocyte epithelial- to-mesenchymal transition via SDF-1\u03b1 in diabetic nephropathy","volume":"8","author":"Chang","year":"2017","journal-title":"Front Pharmacol"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.112.195115","article-title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism","volume":"60","author":"Liu","year":"2012","journal-title":"Hypertension"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/dom.12050","article-title":"Extra-pancreatic effects of incretin-based therapies: Potential benefit for cardiovascular-risk management in type 2 diabetes","volume":"15","author":"van Genugten","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-11-6","article-title":"Saxagliptin for the treatment of type 2 diabetes mellitus: Assessing cardiovascular data","volume":"11","author":"Cobble","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1440-1681.2010.05389.x","article-title":"Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome","volume":"37","author":"Tofovic","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1440-1681.2007.04737.x","article-title":"Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure","volume":"35","author":"Jackson","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00463.2010","article-title":"Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice","volume":"300","author":"Dobrian","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/DMSO.S132537","article-title":"Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a\/Keap-1\/Nrf2 antioxidant pathway","volume":"10","author":"Civantos","year":"2017","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.245277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:49:55Z","timestamp":1623959395000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201811200-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":28,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.245277","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,20]]}}}